ArticleFrontiers in surgery2025
Liver transplantation for HCC within and beyond Milan Criteria: single center experience with literature review.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of Long-Term Outcomes of Living-Donor Liver Transplantation in Hepatocellular Carcinoma Based on the Milan Criteria After Downstaging According to Degradable Starch Microspheres with Transcatheter Arterial Chemoembolization.Life (Basel, Switzerland) · 2026Article
- Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy.Journal of hepatocellular carcinoma · 2026Article
- YKL-40 in Virus-Associated Liver Disease: A Translational Biomarker Linking Fibrosis, Hepatocarcinogenesis, and Liver Transplantation.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Milan Criteria (MC) are widely accepted as the standard patient selection criteria for liver transplantation (LT). However, patients who exceed these criteria may still benefit from transplantation. Various extended criteria have been published. This study aimed to evaluate survival outcomes in hepatocellular carcinoma (HCC) patients undergoing LT, comparing those within and beyond MC, and to review the role of extended criteria in LT. Methods: This retrospective, single-center study included adult patients who underwent LT at Koç University between 2018 and 2024. Pathological data were used to categorize patients into two groups: those within MC and beyond MC. Preoperative data and postoperative overall and disease-free survival rates were compared between these groups. Additionally, a comprehensive literature review of studies evaluating extended criteria for LT in HCC patients was conducted. Results: A total of 45 adult patients were included in the analysis. There were 23(51.1%) patients within MC, and 22(48.9%) patients in the beyond MC group. Demographics, donor types, graft types, tumor differentiations, Child scores, MELD scores, ischemia times, length of intensive care unit stays, length of hospital stays, and mortality rates were similar ( Conclusion: This study highlights the potential for liver transplantation in HCC patients exceeding the Milan Criteria, with survival outcomes comparable to those within the Milan Criteria in certain cases. Despite numerous studies in the literature, optimal criteria for LT patient selection in beyond MC HCC have not been established. An optimal guideline that will help to better understand tumor behavior, guide the decision-making and timing of liver transplantation (LT), and ultimately improve post-transplant outcomes remains a key objective for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.